![Marco Caremi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marco Caremi
Vorstandsvorsitzender bei
Newron Sweden AB
Profil
Marco Caremi is currently working as a Director at Hunter-Fleming Ltd., President & Director at Newron Pharmaceuticals US, Inc., and Co-General Manager at Newron Sweden AB. Previously, he worked as a Director-Business Development at Schwarz Pharma SpA from 1998 to 2002, Sales Representative & Sales Specialist at Polifarma SpA, Manager-Business Development at Schering-Plough SpA from 1996 to 1998, and Executive Vice President-Business Development at Newron Pharmaceuticals SpA from 2002 to 2023.
He completed his undergraduate degree from the University of Milan.
Aktive Positionen von Marco Caremi
| Unternehmen | Position | Beginn |
|---|---|---|
Hunter-Fleming Ltd.
 Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Direktor/Vorstandsmitglied | - |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Vorstandsvorsitzender | - |
Newron Pharmaceuticals US, Inc.
 Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease. | Präsident | - |
Ehemalige bekannte Positionen von Marco Caremi
| Unternehmen | Position | Ende |
|---|---|---|
| NEWRON PHARMACEUTICALS S.P.A. | General Counsel | 01.01.2012 |
Schwarz Pharma SpA | Corporate Officer/Principal | 01.01.2002 |
Schering-Plough SpA | Corporate Officer/Principal | 01.01.1998 |
Polifarma SpA
 Polifarma SpA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for central nervous system, gastroenterology, ophthalmology, cardiology & infectious diseases | Vertrieb & Marketing | - |
Ausbildung von Marco Caremi
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
28
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Hunter-Fleming Ltd.
Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Newron Pharmaceuticals SpA
 Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system | Health Technology |
Newron Sweden AB
Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Health Technology |
University of Milan
 University of Milan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Polifarma SpA
Polifarma SpA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for central nervous system, gastroenterology, ophthalmology, cardiology & infectious diseases | Health Technology |
Schering-Plough SpA | |
Schwarz Pharma SpA | |
Newron Pharmaceuticals US, Inc.
Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease. | Commercial Services |
